Dr. Martha Gulati “Get Vaccinated Please” på Twitter: "Clinical trials Phase III on ORION: Inclisiran vs placebo: 55% LDL reduction on top of lipid lowering therapy #ACC20 https://t.co/mhgNXuKyiJ" / Twitter
RNAi Inclisiran A Novel Approach to PCSK 9
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status - PACE-CME
Inclisiran - Lappin - 2021 - Practical Diabetes - Wiley Online Library
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia | NEJM
Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials | DAIC
References in Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies - Mayo Clinic Proceedings
Cureus | Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists
A) Simplified overview of mechanism of action by Inclisiran.... | Download Scientific Diagram
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
ESC 2019 – Medicines Company impresses with inclisiran | Evaluate
Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials
FAQ — ORION 4
ORION-1 Inclisiran inhibits PCSK9 synthesis by RNA interference Planned interim analysis of a multi-center randomized controlled dose-finding trial Kausik. - ppt download
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
RNAi Inclisiran A Novel Approach to PCSK 9
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender | Novartis
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | NEJM
Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug's Approval | tctmd.com
Is Novartis' RNA Therapeutic Inclisiran Poised to Displace PCSK9 Antibodies and Become the Next Blockbuster Lipid-Lowering Drug?, Brent Osborne, Mike Rice
Leqvio (inclisiran) for the Treatment of Hypercholaesterolemia
Abstract 13503: Relative Efficacy of Alirocumab, Bempedoic Acid, Evolocumab, Ezetimibe and Inclisiran Added to Statins for Reduction of Low Density Lipoprotein Cholesterol - A Network Meta-Analysis of Randomized Clinical Trials | Circulation
The Medicines Company: Limited Upside And A Tough Market Battle For Inclisiran (NASDAQ:MDCO) | Seeking Alpha
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
